Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

New ADEKplus[TM] a Fat Soluble Nutritional Product Launched to Aid Conditions Such as Cystic Fibrosis


News provided by

Mylan

29 Nov, 2016, 11:00 GMT

Share this article

Share toX

Share this article

Share toX

HATFIELD, England, November 29, 2016 /PRNewswire/ --

ADEKplus, a nutritional supplement for people with pancreatic exocrine insufficiency (PEI), is now available online. PEI results in the inability to digest food properly and therefore insufficient absorption of vital, fat-soluble vitamins A, D, E and K.[1] PEI is commonly found in people with cystic fibrosis, as well as other diseases that affect the pancreas, such as chronic pancreatitis.[1]

New ADEKplus provides vitamins A, D, E and K in one chewable, pleasant tasting, multivitamin tablet, providing a welcome alternative for people with cystic fibrosis who often need to take multiple vitamin supplements daily, adding to an already overwhelming regime of medication.[2]

Cystic fibrosis is one of the UK's most common life-threatening inherited diseases, affecting 10,500 people in the UK.[3] The nutritional needs of people living with cystic fibrosis are far more complex than those of healthy individuals. Sufficient intake of fats, essential fatty acids, proteins, sugars, probiotics and vitamins is essential for digestive health and helping to avoid common complications such as weight loss and chest infections.  

Specifically for people with pancreatic exocrine insufficiency, ADEKplus, launched by Mylan N.V., a leading global pharmaceutical company, provides vitamins A, D, E and K which are essential to body function and overall health:

  • Vitamin A - is important for normal vision, bone and tooth formation, the immune system and keeping the intestines healthy[4]
  • Vitamin D - helps to maintain strong bones and teeth. Without enough vitamin D, bones can become thin and brittle. People with cystic fibrosis are particularly at risk of bone problems[4]
  • Vitamin E - is one of the main antioxidants. It also keeps red blood cells healthy, fights infection and maintains intestinal health[4]
  • Vitamin K - important for blood clotting and bone health[4]

"ADEKplus has made life much easier. Having vitamins A, D, E and K together in one tablet has allowed me to rid myself of taking extra vitamin tablets each day, meaning that the mountain of vitamin tablets I take is a little closer to becoming a molehill. It's much more convenient and I know it's providing me with the vitamins I need," said Liz Norton, cystic fibrosis patient at the Brompton Hospital.

Resulting from a single defective gene, cystic fibrosis causes the internal organs, especially the lungs and digestive system, to become clogged with thick sticky mucus resulting in chronic infections and inflammation in the lungs and difficulty digesting food. Only around 10% of people with cystic fibrosis retain any useful pancreatic function, meaning that digestive juices (enzymes) are not secreted into the intestine in order to break down food properly so that the body can use it to stay healthy and produce energy.[5]

"Despite there still being no cure for cystic fibrosis, we are starting to see improvements in survival rates thanks to advances in treatment and care. This often means taking numerous[6] tablets per day, as well as measures to prevent cross-infection, a multitude of treatments such as physiotherapy and frequent hospital visits and stays. A body supplied with the correct level of nutrients and operating to the best of its ability is less prone to infection and unwanted weight loss, thus less time in hospital and fewer drugs overall," said Mylan's UK Managing Director, Jean-Yves Brault.

ADEKplus has been formulated in line with the 2013 Royal Brompton Hospital's guidelines which aim to ensure a standard approach to care for adults[7] and children[8] with cystic fibrosis. ADEKplus should only be consumed by people with exocrine pancreatic insufficiency. The recommended dose is 1 - 2 tablets per day as directed by a doctor or a qualified healthcare professional. ADEKplus is available online at http://www.adekplus.co.uk. ADEKplus is not intended for children under two years of age unless recommended by a healthcare professional. 

NOTES TO EDITOR 

Cystic Fibrosis 

Cystic fibrosis is a life-threatening, genetic disease that causes persistent lung infections and progressively limits the ability to breathe. In people with cystic fibrosis, a defective gene causes a thick, buildup of mucus in the lungs, pancreas and other organs. In the lungs, the mucus clogs the airways and traps bacteria leading to infections, extensive lung damage and eventually, respiratory failure. In the pancreas, the mucus prevents the release of digestive enzymes that allow the body to break down food and absorb vital nutrients.[9] Over 2 million people in the UK carry the faulty gene and around 10,500 people in the UK have cystic fibrosis, that's one in every 2,500 babies born.[10]

Exocrine pancreatic insufficiency (EPI) 

Exocrine pancreatic insufficiency is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in the inability to digest food properly. EPI is associated with certain diseases and conditions that affect the pancreas such as Cystic Fibrosis.[11]

ADEKplus  

ADEKplus has been formulated in line with the 2013 Royal Brompton Hospital's guidelines. The purpose of the guidelines is to ensure a standard approach to care for adults and children with cystic fibrosis.

ADEKplus should only be consumed by people with exocrine pancreatic insufficiency. The recommended dose is 1 - 2 tablets per day as directed by a doctor or a qualified healthcare professional. ADEKplus is not intended for children under two years of age unless recommended by a healthcare professional.

People taking anti-coagulants (blood thinners) should not take ADEKplus unless advised to by their doctor. ADEKplus cannot be used as a sole source of nutrition. ADEKplus should not be taken by people allergic to any of the ingredients. Any unwanted side effects should be reported to an appropriate healthcare professional.

About Mylan 

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 2,700 generic and branded pharmaceuticals, including antiretroviral therapies on which approximately 50% of people being treated for HIV/AIDS worldwide depend. We market our products in more than 165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities, and we are one of the world's largest producers of active pharmaceutical ingredients. Every member of our more than 40,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com.

References 

1. Exocrine Pancreatic Insufficiency. The National Pancreas Foundation. https://www.pancreasfoundation.org/patient-information/ailments-pancreas/exocrine-pancreatic-insufficiency/ Last accessed October 2016. 

2. Data on file, Mylan N.V. 

3. Frequently Asked Questions. Cystic Fibrosis Trust. https://www.cysticfibrosis.org.uk/what-is-cystic-fibrosis/faqs#basics  Last accessed October 2016. 

4. Vitamins. Cystic Fibrosis Foundation. https://www.cff.org/Living-with-CF/Treatments-and-Therapies/Nutrition/Vitamins/ Last accessed October 2016. 

5. Nutrition. Cystic Fibrosis Trust.  https://www.cysticfibrosis.org.uk/life-with-cystic-fibrosis/cystic-fibrosis-care/nutrition  Last accessed October 2016. 

6. NHS Choices. Treating Cystic Fibrosis. http://www.nhs.uk/Conditions/cystic-fibrosis/Pages/treatment.aspx#medicines  Last accessed October 2016 

7. Care of Adults with Cystic Fibrosis (2013), Royal Brompton and Harefield NHS Trust. http://www.rbht.nhs.uk/healthprofessionals/clinical-departments/cystic-fibrosis/clinical-guidelines/ Last accessed October 2016. 

8. Care of Children with Cystic Fibrosis (2014), Royal Brompton and Harefield NHS Trust. http://www.rbht.nhs.uk/healthprofessionals/clinical-departments/paediatrics/childrencf/ 

9. About Cystic Fibrosis. Cystic Fibrosis Foundation. https://www.cff.org/What-is-CF/About-Cystic-Fibrosis/ Last accessed October 2016. 

10. What is Cystic Fibrosis? Cystic Fibrosis Trust. https://www.cysticfibrosis.org.uk/what-is-cystic-fibrosis Last accessed October 2016. 

11. Exocrine Pancreatic Insufficiency. The National Pancreas Foundation. https://www.pancreasfoundation.org/patient-information/ailments-pancreas/exocrine-pancreatic-insufficiency/ Last accessed October 2016. 

Date of Preparation : Nov 2016

Ref: NON-2016-1116

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.